Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

© GettyImages/Design Cells

AstraZeneca invests in saRNA specialist

By Jane Byrne

AstraZeneca has announced a long-term research collaboration with VaxEquity for the discovery, development and commercialization of its self-amplifying RNA (saRNA) therapeutics platform.

DRI plans to demonstrate the capacity to manufacture adjuvant at large scale

IDRI receives $4m from BARDA to create adjuvant manufacturing hub

By Zachary Brennan

Seattle-based Infectious Disease Research Institute (IDRI) has received $4m in funding from the US Biomedical Advanced Research and Development Authority (BARDA) to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to...

The new modular guideline is intended to update in a consolidated document the existing guidance

EMA revises guidance on developing flu vaccines

By Zachary Brennan

The European Medicines Agency (EMA) has released a second module of a new guideline on influenza vaccines for a six-month public consultation, which covers the non-clinical and clinical requirements for the development of new flu vaccines.